Daihan PharmaceuticalLtd Past Earnings Performance
Past criteria checks 3/6
Daihan PharmaceuticalLtd's earnings have been declining at an average annual rate of -1.5%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 3.9% per year. Daihan PharmaceuticalLtd's return on equity is 11.5%, and it has net margins of 14.5%.
Key information
-1.5%
Earnings growth rate
-1.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 3.9% |
| Return on equity | 11.5% |
| Net Margin | 14.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly
Mar 02
Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Feb 09
Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?
Jan 19What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?
Dec 18Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?
Nov 27Revenue & Expenses BreakdownBeta
How Daihan PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 195,911 | 28,426 | 26,956 | 1,641 |
| 30 Sep 23 | 194,528 | 26,211 | 26,654 | 1,425 |
| 30 Jun 23 | 192,259 | 26,521 | 26,207 | 617 |
| 31 Mar 23 | 189,043 | 26,089 | 25,994 | 607 |
| 31 Dec 22 | 184,268 | 24,961 | 25,411 | 568 |
| 30 Sep 22 | 181,122 | 26,197 | 25,482 | 556 |
| 30 Jun 22 | 177,126 | 25,029 | 25,050 | 476 |
| 31 Mar 22 | 173,726 | 23,690 | 24,985 | 586 |
| 31 Dec 21 | 171,463 | 22,670 | 24,781 | 791 |
| 30 Sep 21 | 166,619 | 16,680 | 24,212 | 977 |
| 30 Jun 21 | 165,495 | 16,166 | 24,362 | 1,035 |
| 31 Mar 21 | 162,372 | 15,568 | 24,471 | 909 |
| 31 Dec 20 | 166,080 | 17,381 | 24,573 | 689 |
| 30 Sep 20 | 170,116 | 26,246 | 25,185 | 384 |
| 30 Jun 20 | 170,011 | 26,438 | 24,809 | 396 |
| 31 Mar 20 | 172,492 | 28,702 | 24,345 | 393 |
| 31 Dec 19 | 168,762 | 28,167 | 24,237 | 392 |
| 30 Sep 19 | 165,178 | 27,408 | 23,217 | 494 |
| 30 Jun 19 | 161,926 | 27,618 | 23,535 | 476 |
| 31 Mar 19 | 158,298 | 28,256 | 22,363 | 467 |
| 31 Dec 18 | 158,720 | 28,518 | 22,747 | 458 |
| 30 Sep 18 | 153,402 | 26,631 | 21,909 | 431 |
| 30 Jun 18 | 152,130 | 27,449 | 21,857 | 409 |
| 31 Mar 18 | 149,083 | 26,148 | 22,383 | 397 |
| 31 Dec 17 | 144,439 | 24,832 | 21,427 | 382 |
| 30 Sep 17 | 145,319 | 23,702 | 21,863 | 394 |
| 30 Jun 17 | 140,743 | 21,183 | 21,021 | 393 |
| 31 Mar 17 | 140,077 | 18,881 | 20,847 | 394 |
| 31 Dec 16 | 139,437 | 17,657 | 20,688 | 410 |
| 30 Sep 16 | 134,843 | 16,853 | 20,510 | 403 |
| 30 Jun 16 | 131,994 | 15,774 | 20,249 | 397 |
| 31 Mar 16 | 128,845 | 15,285 | 20,033 | 461 |
| 31 Dec 15 | 124,276 | 13,776 | 20,002 | 356 |
| 30 Sep 15 | 121,296 | 12,275 | 20,082 | 257 |
| 30 Jun 15 | 118,698 | 11,126 | 20,292 | 212 |
| 31 Mar 15 | 114,739 | 9,817 | 20,051 | 68 |
| 31 Dec 14 | 111,709 | 10,420 | 19,445 | 68 |
| 30 Sep 14 | 109,610 | 10,000 | 18,340 | 114 |
| 30 Jun 14 | 107,834 | 7,924 | 17,729 | 82 |
| 31 Mar 14 | 107,229 | 8,305 | 17,208 | 61 |
| 31 Dec 13 | 106,803 | 7,771 | 16,859 | 92 |
| 30 Sep 13 | 105,028 | 7,655 | 15,783 | 631 |
| 30 Jun 13 | 102,700 | 9,145 | 15,408 | 631 |
Quality Earnings: A023910 has high quality earnings.
Growing Profit Margin: A023910's current net profit margins (14.5%) are higher than last year (13.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A023910's earnings have declined by 1.5% per year over the past 5 years.
Accelerating Growth: A023910's earnings growth over the past year (13.9%) exceeds its 5-year average (-1.5% per year).
Earnings vs Industry: A023910 earnings growth over the past year (13.9%) did not outperform the Pharmaceuticals industry 36.1%.
Return on Equity
High ROE: A023910's Return on Equity (11.5%) is considered low.